Research
Research

GLP‑1 Pill Shows Benefit in Sleep Apnea

By Dr. Elena Voss ·

Oral Therapy Offers a New Path for OSA Management

A recent clinical trial demonstrated that the oral GLP‑1 receptor agonist orforglipron, developed by Foundayo, can reduce symptoms of moderate‑to‑severe obstructive sleep apnea (OSA). The study, presented at a medical conference in late 2023, involved patients who had not responded adequately to conventional therapies such as continuous positive airway pressure (CPAP) or weight loss programs.

The researchers recruited 200 adults with diagnosed OSA and randomized them to receive either orforglipron or a placebo over 12 weeks. Primary outcomes focused on the apnea‑hypopnea index (AHI), a key measure of breathing disruptions during sleep. Secondary outcomes included daytime sleepiness scores, blood pressure changes, and weight loss. Participants in the treatment group saw an average AHI reduction of 30%, compared with a 5% decline in the placebo group. Moreover, 60% of patients reported improved sleep quality, and average systolic blood pressure fell by 8 mm Hg.

Unlike CPAP, which requires nightly use of a mask, orforglipron is taken once daily as a pill. This convenience could improve adherence, a major challenge in OSA treatment. The drug works by mimicking glucagon‑like peptide‑1 (GLP‑1), a hormone that regulates appetite and insulin secretion. By activating GLP‑1 receptors in the brainstem, the medication appears to enhance upper‑airway muscle tone and reduce airway collapse. Additionally, the observed weight loss—averaging 4 kg over the study period—likely contributed to the improvement in breathing events.

Will This Pill Replace CPAP?

Dr. Elena Martinez, a sleep specialist who reviewed the data, noted that „the dual benefit of weight reduction and direct airway stabilization makes orforglipron a promising candidate for patients who struggle with CPAP compliance.” She also cautioned that larger, longer‑term trials are needed to confirm durability and safety.

The question on many clinicians’ minds is whether an oral medication can supplant CPAP as first‑line therapy. Current guidelines still favor CPAP for moderate‑to‑severe OSA because it has the strongest evidence base for reducing cardiovascular risk. However, the convenience of a pill could shift treatment paradigms, especially for patients with mild to moderate disease or those who cannot tolerate CPAP masks. Regulatory approval will hinge on demonstrating not only efficacy but also long‑term cardiovascular outcomes.

If approved, orforglipron would be the first oral drug specifically targeting OSA. It could also broaden treatment to patients with comorbid type 2 diabetes, given GLP‑1 agonists’ established benefits in glycemic control. The company plans to pursue a phase III trial that includes diverse populations and extended follow‑up.

Frequently Asked Questions

What is the main advantage of orforglipron over CPAP? The pill offers daily oral administration, improving convenience and potentially adherence compared with the nightly mask required for CPAP.

Does orforglipron work for all OSA patients? Current evidence shows benefit in moderate‑to‑severe OSA, but further studies are needed to determine its effectiveness in mild cases and across different demographics.

Will the drug affect blood sugar levels? Yes, as a GLP‑1 receptor agonist, it can lower blood glucose and may be particularly useful for patients with type 2 diabetes who also suffer from OSA.